{"pmid":32298856,"title":"From the insight of glucose metabolism disorder: Oxygen therapy and blood glucose monitoring are crucial for quarantined COVID-19 patients.","text":["From the insight of glucose metabolism disorder: Oxygen therapy and blood glucose monitoring are crucial for quarantined COVID-19 patients.","Ecotoxicol Environ Saf","Li, Zhi","Liu, Guoliang","Wang, Ling","Liang, Yong","Zhou, Qunfang","Wu, Fei","Yao, Jing","Chen, Bolei","32298856"],"journal":"Ecotoxicol Environ Saf","authors":["Li, Zhi","Liu, Guoliang","Wang, Ling","Liang, Yong","Zhou, Qunfang","Wu, Fei","Yao, Jing","Chen, Bolei"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298856","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ecoenv.2020.110614","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266651293450241,"score":8.233237,"similar":[{"pmid":32220179,"title":"[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","text":["[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients.","Sichuan Da Xue Xue Bao Yi Xue Ban","Ma, Wan-Xia","Ran, Xing-Wu","32220179"],"abstract":["Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients."],"journal":"Sichuan Da Xue Xue Bao Yi Xue Ban","authors":["Ma, Wan-Xia","Ran, Xing-Wu"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220179","week":"202013|Mar 23 - Mar 29","doi":"10.12182/20200360606","keywords":["Blood glucose level","Blood glucose monitoring","Coronavirus disease 2019, COVID-19","Diabetes mellitus","Inpatient glycemic control","Insulin","Therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Blood Glucose"],"_version_":1663352135093321728,"score":142.63159},{"pmid":32220612,"pmcid":"PMC7102634","title":"Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China.","text":["Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China.","Metabolism","Zhou, Jun","Tan, Jie","32220612"],"journal":"Metabolism","authors":["Zhou, Jun","Tan, Jie"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220612","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.metabol.2020.154216","source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352135164624898,"score":115.94679},{"pmid":32179126,"pmcid":"PMC7102524","title":"Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed.","text":["Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed.","Diabetes Res Clin Pract","Wang, Aihong","Zhao, Weibo","Xu, Zhangrong","Gu, Jianwen","32179126"],"journal":"Diabetes Res Clin Pract","authors":["Wang, Aihong","Zhao, Weibo","Xu, Zhangrong","Gu, Jianwen"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32179126","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.diabres.2020.108118","source":"PubMed","topics":["Prevention"],"weight":1,"e_drugs":["Blood Glucose"],"_version_":1663352133868584960,"score":93.13218},{"pmid":32247323,"title":"Monitoring behavioural insights related to COVID-19.","text":["Monitoring behavioural insights related to COVID-19.","Lancet","Betsch, Cornelia","Wieler, Lothar H","Habersaat, Katrine","32247323"],"journal":"Lancet","authors":["Betsch, Cornelia","Wieler, Lothar H","Habersaat, Katrine"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247323","week":"202015|Apr 06 - Apr 12","doi":"10.1016/S0140-6736(20)30729-7","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663352136169160704,"score":62.423145},{"pmid":32301347,"title":"Extracorporeal membrane oxygenation therapy in the COVID-19 pandemic.","text":["Extracorporeal membrane oxygenation therapy in the COVID-19 pandemic.","Future Cardiol","Pravda, Nili Schamroth","Pravda, Miri Schamroth","Kornowski, Ran","Orvin, Katia","32301347"],"journal":"Future Cardiol","authors":["Pravda, Nili Schamroth","Pravda, Miri Schamroth","Kornowski, Ran","Orvin, Katia"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301347","week":"202016|Apr 13 - Apr 19","doi":"10.2217/fca-2020-0040","keywords":["covid-19","ecmo","extracorporeal membrane oxygenation therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664357978615054336,"score":52.684967}]}